The U.S. Food and Drug Administration has approved the SetPoint System, a neuroimmune modulation device for the treatment of adults living with moderate-to-severe rheumatoid arthritis (RA).

Axonics Modulation Technologies (AXNX) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2022. This widely ...